Omalizumab for prevention of anaphylactic episodes in a patient with severe mosquito allergy
Abstract Anaphylaxis after mosquito bite is rare, but life threatening. No approved preventive therapy is available to date, but omalizumab could be a promising therapeutic option for reducing risk and improving quality of life in these patients.
Saved in:
Main Authors: | Elisa Meucci, Anna Radice, Filippo Fassio, Maria Loredana Chiara Iorno, Donatella Macchia |
---|---|
Format: | article |
Language: | EN |
Published: |
Wiley
2021
|
Subjects: | |
Online Access: | https://doaj.org/article/5e76b6d89eee413f87ad7fef882ea071 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Tratamiento del asma severo con Omalizumab: experiencia pediátrica en Chile y revisión de la literatura
by: HERRERA G,ANA MARÍA, et al.
Published: (2016) -
Exploring Machine Learning Techniques to Predict the Response to Omalizumab in Chronic Spontaneous Urticaria
by: Davide Stefano Sardina, et al.
Published: (2021) -
Inhibitory effect of a new orally active cedrol-loaded nanostructured lipid carrier on compound 48/80-induced mast cell degranulation and anaphylactic shock in mice
by: Chakraborty S, et al.
Published: (2017) -
Two decades with omalizumab: what we still have to learn
by: Incorvaia C, et al.
Published: (2018) -
Anaphylactic Reactions Due to <i>Triatoma protracta</i> (Hemiptera, Reduviidae, Triatominae) and Invasion into a Home in Northern California, USA
by: Norman L. Beatty, et al.
Published: (2021)